Eyebright Medical Technology (Beijing) Co., Ltd. (688050.SS)
CNY 79.03
(1.18%)
CNY 79.03
(1.18%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -146.6 Million CNY | 23.69% |
| 2022 | -192.1 Million CNY | 39.59% |
| 2021 | -318.02 Million CNY | 40.45% |
| 2020 | -534.06 Million CNY | -173.27% |
| 2019 | -195.43 Million CNY | -224.85% |
| 2018 | -60.16 Million CNY | -707.05% |
| 2017 | 9.91 Million CNY | 139.86% |
| 2016 | -24.86 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 139.45 Million CNY | 267.82% |
| 2024 Q1 | 37.91 Million CNY | 125.86% |
| 2023 Q4 | -146.6 Million CNY | 61.87% |
| 2023 FY | -146.6 Million CNY | 23.69% |
| 2023 Q2 | -95.04 Million CNY | 32.63% |
| 2023 Q1 | -141.07 Million CNY | 26.57% |
| 2023 Q3 | -384.5 Million CNY | -304.55% |
| 2022 Q3 | -93.06 Million CNY | 37.67% |
| 2022 Q1 | 5.1 Million CNY | 101.61% |
| 2022 FY | -192.1 Million CNY | 39.59% |
| 2022 Q4 | -192.1 Million CNY | -106.42% |
| 2022 Q2 | -149.3 Million CNY | -3024.85% |
| 2021 Q2 | -241.68 Million CNY | 18.42% |
| 2021 FY | -318.02 Million CNY | 40.45% |
| 2021 Q1 | -296.25 Million CNY | 44.53% |
| 2021 Q4 | -318.02 Million CNY | 18.3% |
| 2021 Q3 | -389.27 Million CNY | -61.06% |
| 2020 FY | -534.06 Million CNY | -173.27% |
| 2020 Q4 | -534.06 Million CNY | -15.51% |
| 2020 Q3 | -462.37 Million CNY | -170.05% |
| 2020 Q2 | -171.21 Million CNY | 3.52% |
| 2020 Q1 | -177.45 Million CNY | 9.2% |
| 2019 FY | -195.43 Million CNY | -224.85% |
| 2019 Q2 | -199.05 Million CNY | -173.58% |
| 2019 Q3 | - CNY | 100.0% |
| 2019 Q4 | -195.43 Million CNY | 0.0% |
| 2019 Q1 | 270.52 Million CNY | 549.68% |
| 2018 FY | -60.16 Million CNY | -707.05% |
| 2018 Q4 | -60.16 Million CNY | 0.0% |
| 2017 FY | 9.91 Million CNY | 139.86% |
| 2016 FY | -24.86 Million CNY | 0.0% |